Understand the source comparison
Best Peptides for Peripheral Neuropathy: Evidence & Mechanism Comparison
BPC-157 VEGF upregulation, FAK-paxillin pathway activation → axonal outgrowth Rat sciatic nerve transection model: 40% faster motor recovery vs saline (2020, Eur J Pharmacol) 250–500mcg SubQ daily No Phase 2+ human trials in neuropathy populations Strongest pr
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, FAK-paxillin pathway activation → axonal outgrowth
- Rat sciatic nerve transection model: 40% faster motor recovery vs saline (2020, Eur J Pharmacol)
- 250–500mcg SubQ daily
- No Phase 2+ human trials in neuropathy populations
- Strongest preclinical nerve regeneration data; mechanism directly targets structural repair
- Cerebrolysin
- Neurotrophic factor delivery (BDNF, GDNF, CNTF) → neurogenesis, synaptic plasticity
- 19-trial meta-analysis in stroke: significant neurological improvement correlated with BDNF increase (2018, CNS Drugs)
- 30–60mL IV over 10–21 days
- Mixed Phase 3 stroke results; no peripheral nerve trials
- CNS evidence strong; peripheral translation unproven but mechanistically plausible
- Thymosin Beta-4
- Actin polymerization, angiogenesis, anti-inflammatory cytokine modulation
- Myocardial infarction models: reduced scar tissue, increased vascular density (Ann NY Acad Sci)
- 2–10mg SubQ weekly
- Phase 2 cardiac trial terminated (recruitment issues); zero neuropathy trials
- Angiogenic mechanism relevant to microvascular neuropathy; clinical data entirely absent
- Dihexa
- HGF/c-Met pathway activation → synaptic density increase
- Alzheimer's rodent models: 10× more potent than BDNF at promoting synaptogenesis (2017, ACS Chem Neurosci)
- 1–5mg oral daily (research)
- Exclusively CNS-focused research; no peripheral nerve models published
- Potent CNS neurogenic effects; unknown whether mechanism extends to PNS
- P21
- CNTF mimetic → neuroprotection, axonal sprouting
- Retinal ganglion cell injury models: dose-dependent cell survival increase (2015, Exp Eye Res)
- 1–10mg SubQ 2–3x/week
- Narrow research focus (retinal/CNS); no systemic neuropathy studies
- Mechanism overlaps with nerve repair pathways; evidence base extremely limited